Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years

被引：0
|
作者：
X Baraliakos
J Brandt
J Listing
J Sieper
J Braun
机构：
[1] Rheumatology Medical Center Ruhrgebiet,
[2] German Rheumatism Research Center,undefined
[3] University Medicine Berlin,undefined
来源：
Arthritis Research & Therapy | / 7卷
关键词：
Infliximab; Ankylose Spondylitis; Open Label Extension; Infliximab Treatment; Relevant Side Effect;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease
    Zaccagna, A
    Bertone, A
    Puiatti, P
    Picciotto, F
    Sprujevnik, T
    Santucci, R
    Rossini, FP
    EUROPEAN JOURNAL OF DERMATOLOGY, 2003, 13 (03) : 258 - 260
  • [22] Combination therapy of the chimeric monoclonal anti-tumor necrosis factor α antibody (infliximab) with methotrexate in patients with rheumatoid arthritis
    Antoni, C
    Kalden, JR
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1999, 17 (06) : S73 - S77
  • [23] Management of Inflammatory Bowel Disease with Infliximab and Other Anti-Tumor Necrosis Factor Alpha Therapies
    Fernando Magro
    Francisco Portela
    BioDrugs, 2010, 24 : 3 - 14
  • [24] Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis
    Wu, Dan
    Guo, Ying-Ying
    Xu, Nan-Nan
    Zhao, Shuai
    Hou, Lin-Xin
    Jiao, Ting
    Zhang, Ning
    BMC MUSCULOSKELETAL DISORDERS, 2015, 16
  • [25] An update on the use of tumor necrosis factor alpha inhibitors in the treatment of ankylosing spondylitis
    Osman, Mohammed S.
    Maksymowych, Walter P.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (02) : 125 - 131
  • [26] Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis
    Stone, M
    Salonen, D
    Lax, M
    Payne, U
    Lapp, V
    Inman, R
    JOURNAL OF RHEUMATOLOGY, 2001, 28 (07) : 1605 - 1614
  • [27] Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy
    Kwon, Seong-Ryul
    Lim, Mie-Jin
    Suh, Chang-Hee
    Park, Shin-Goo
    Hong, Yeon-Sik
    Yoon, Bo-Young
    Kim, Hyoun-Ah
    Choi, Hyo-Jin
    Park, Won
    RHEUMATOLOGY INTERNATIONAL, 2012, 32 (08) : 2523 - 2527
  • [28] Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?
    Carla GS Saad
    Ana CM Ribeiro
    Julio CB Moraes
    Liliam Takayama
    Celio R Goncalves
    Marcelo B Rodrigues
    Ricardo M de Oliveira
    Clovis A Silva
    Eloisa Bonfa
    Rosa MR Pereira
    Arthritis Research & Therapy, 14
  • [29] Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?
    Saad, Carla G. S.
    Ribeiro, Ana C. M.
    Moraes, Julio C. B.
    Takayama, Liliam
    Goncalves, Celio R.
    Rodrigues, Marcelo B.
    de Oliveira, Ricardo M.
    Silva, Clovis A.
    Bonfa, Eloisa
    Pereira, Rosa M. R.
    ARTHRITIS RESEARCH & THERAPY, 2012, 14 (05)
  • [30] Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis
    Tilg, H
    Jalan, R
    Kaser, A
    Davies, NA
    Offner, FA
    Hodges, SJ
    Ludwiczek, O
    Shawcross, D
    Zoller, H
    Alisa, A
    Mookerjee, RP
    Graziadei, N
    Datz, C
    Trauner, M
    Schuppan, D
    Obrist, P
    Vogel, W
    Williams, R
    JOURNAL OF HEPATOLOGY, 2003, 38 (04) : 419 - 425
12345